Effie W Petersdorf1,2, Mats Bengtsson3, Dianne De Santis4, Valerie Dubois5, Katharina Fleischhauer6, Ted Gooley1, Mary Horowitz7,8, J Alejandro Madrigal9, Mari Malkki1, Caroline McKallor1, Yasuo Morishima10, Machteld Oudshoorn11,12, Stephen R Spellman13, Jean Villard14, Phil Stevenson1, Mary Carrington15,16. 1. Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA. 2. Department of Medicine, University of Washington, Seattle, WA. 3. Department of Immunology, Genetics, and Pathology, University of Uppsala, Uppsala, Sweden. 4. PathWest, Fiona Stanley Hospital, Perth, WA, Australia. 5. Etablissement Français du Sang Auvergne Rhône Alpes, site de Lyon, Décines, France. 6. Institute for Experimental Cellular Therapy, University of Duisburg-Essen, Essen, Germany. 7. Center for International Blood and Marrow Transplant Research, Milwaukee, WI. 8. Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI. 9. Anthony Nolan Research Institute, Royal Free Hospital, London, United Kingdom. 10. Aichi Medical University School of Medicine, Nagakute, Aichi, Japan. 11. Leiden University Medical Centre, Department Immunohematology and Blood Transfusion, Leiden, the Netherlands. 12. Matchis Foundation, Leiden, the Netherlands. 13. Center for International Blood and Marrow Transplant Research, Minneapolis, MN. 14. Geneva University Hospital, Geneva, Switzerland. 15. Basic Science Program, Frederick National Laboratory for Cancer Research, Frederick, MD. 16. Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University, Cambridge, MA.
Abstract
PURPOSE: The main aim of this study was to evaluate the significance of HLA-DPB1 expression in acute graft-versus-host disease (GVHD) after hematopoietic cell transplantation (HCT) from HLA-A, -B, -C, -DRB1, -DQB1-matched and -mismatched unrelated donors. PATIENTS AND METHODS: Between January 1, 2017, and January 10, 2019, we assessed 19,136 patients who received HCT from an HLA-A, -B, -C, -DRB1, -DQB1-matched or -mismatched unrelated donor performed in Australia, the European Union, Japan, North America, and the United Kingdom between 1988 and 2016. Among transplant recipients with one HLA-DPB1 mismatch, the patient's mismatched HLA-DPB1 allotype was defined as low or high expression. Multivariable regression models were used to assess risks of GVHD associated with high expression relative to low expression HLA-DPB1 mismatches. The effect of increasing numbers of HLA-DPB1 mismatches on clinical outcome was assessed in HLA-mismatched transplant recipients. RESULTS: In HLA-A, -B, -C, -DRB1,-DQB1-matched transplant recipients, donor mismatching against one high-expression patient HLA-DPB1 increased moderate (odds ratio [OR], 1.36; P = .001) and severe acute GVHD (OR, 1.32; P = .0016) relative to low-expression patient mismatches, regardless of the expression level of the donor's mismatched HLA-DPB1. Among transplant recipients with one HLA-A, -B, -C, -DRB1, or -DQB1 mismatch, the odds of acute GVHD increased with increasing numbers of HLA-DPB1 mismatches (OR, 1.23 for one; OR, 1.40 for two mismatches relative to zero mismatches for moderate GVHD; OR, 1.19 for one; OR, 1.40 for two mismatches relative to zero for severe GVHD), but not with the level of expression of the patient's mismatched HLA-DPB1 allotype. CONCLUSION: The level of expression of patient HLA-DPB1 mismatches informs the risk of GVHD after HLA-A, -B, -C, -DRB1, -DQB1-matched unrelated HCT, and the total number of HLA-DPB1 mismatches informs the risk of GVHD after HLA-mismatched unrelated HCT. Prospective consideration of HLA-DPB1 may help to lower GVHD risks after transplantation.
PURPOSE: The main aim of this study was to evaluate the significance of HLA-DPB1 expression in acute graft-versus-host disease (GVHD) after hematopoietic cell transplantation (HCT) from HLA-A, -B, -C, -DRB1, -DQB1-matched and -mismatched unrelated donors. PATIENTS AND METHODS: Between January 1, 2017, and January 10, 2019, we assessed 19,136 patients who received HCT from an HLA-A, -B, -C, -DRB1, -DQB1-matched or -mismatched unrelated donor performed in Australia, the European Union, Japan, North America, and the United Kingdom between 1988 and 2016. Among transplant recipients with one HLA-DPB1 mismatch, the patient's mismatched HLA-DPB1 allotype was defined as low or high expression. Multivariable regression models were used to assess risks of GVHD associated with high expression relative to low expression HLA-DPB1 mismatches. The effect of increasing numbers of HLA-DPB1 mismatches on clinical outcome was assessed in HLA-mismatched transplant recipients. RESULTS: In HLA-A, -B, -C, -DRB1,-DQB1-matched transplant recipients, donor mismatching against one high-expression patientHLA-DPB1 increased moderate (odds ratio [OR], 1.36; P = .001) and severe acute GVHD (OR, 1.32; P = .0016) relative to low-expression patient mismatches, regardless of the expression level of the donor's mismatched HLA-DPB1. Among transplant recipients with one HLA-A, -B, -C, -DRB1, or -DQB1 mismatch, the odds of acute GVHD increased with increasing numbers of HLA-DPB1 mismatches (OR, 1.23 for one; OR, 1.40 for two mismatches relative to zero mismatches for moderate GVHD; OR, 1.19 for one; OR, 1.40 for two mismatches relative to zero for severe GVHD), but not with the level of expression of the patient's mismatched HLA-DPB1 allotype. CONCLUSION: The level of expression of patientHLA-DPB1 mismatches informs the risk of GVHD after HLA-A, -B, -C, -DRB1, -DQB1-matched unrelated HCT, and the total number of HLA-DPB1 mismatches informs the risk of GVHD after HLA-mismatched unrelated HCT. Prospective consideration of HLA-DPB1 may help to lower GVHD risks after transplantation.
Authors: K Gagne; P Loiseau; V Dubois; F Dufossé; P Perrier; A Dormoy; I Jollet; V Renac; D Masson; C Picard; X Lafarge; D Hanau; F Quainon; F Delbos; B Coeffic; Léna Absi; J-F Eliaou; V Moalic; M Fort; M de Matteis; I Theodorou; F Hau; A Batho; B Pedron; S Caillat-Zucman; E Marry; N Raus; I Yakoub-Agha; A Cesbron Journal: Bone Marrow Transplant Date: 2014-11-03 Impact factor: 5.483
Authors: E W Petersdorf; T Gooley; M Malkki; C Anasetti; P Martin; A Woolfrey; A Smith; E Mickelson; J A Hansen Journal: Br J Haematol Date: 2001-03 Impact factor: 6.998
Authors: E W Petersdorf; A G Smith; E M Mickelson; G M Longton; C Anasetti; S Y Choo; P J Martin; J A Hansen Journal: Blood Date: 1993-04-01 Impact factor: 22.113
Authors: Marcelo A Fernández-Viña; John P Klein; Michael Haagenson; Stephen R Spellman; Claudio Anasetti; Harriet Noreen; Lee Ann Baxter-Lowe; Pedro Cano; Neal Flomenberg; Dennis L Confer; Mary M Horowitz; Machteld Oudshoorn; Effie W Petersdorf; Michelle Setterholm; Richard Champlin; Stephanie J Lee; Marcos de Lima Journal: Blood Date: 2013-04-17 Impact factor: 22.113
Authors: Stephanie J Lee; John Klein; Michael Haagenson; Lee Ann Baxter-Lowe; Dennis L Confer; Mary Eapen; Marcelo Fernandez-Vina; Neal Flomenberg; Mary Horowitz; Carolyn K Hurley; Harriet Noreen; Machteld Oudshoorn; Effie Petersdorf; Michelle Setterholm; Stephen Spellman; Daniel Weisdorf; Thomas M Williams; Claudio Anasetti Journal: Blood Date: 2007-09-04 Impact factor: 22.113
Authors: Veron Ramsuran; Vivek Naranbhai; Amir Horowitz; Ying Qi; Maureen P Martin; Yuko Yuki; Xiaojiang Gao; Victoria Walker-Sperling; Gregory Q Del Prete; Douglas K Schneider; Jeffrey D Lifson; Jacques Fellay; Steven G Deeks; Jeffrey N Martin; James J Goedert; Steven M Wolinsky; Nelson L Michael; Gregory D Kirk; Susan Buchbinder; David Haas; Thumbi Ndung'u; Philip Goulder; Peter Parham; Bruce D Walker; Jonathan M Carlson; Mary Carrington Journal: Science Date: 2018-01-04 Impact factor: 47.728
Authors: Thuja Meurer; Esteban Arrieta-Bolaños; Maximilian Metzing; Mona-May Langer; Peter van Balen; J H Frederik Falkenburg; Dietrich W Beelen; Peter A Horn; Katharina Fleischhauer; Pietro Crivello Journal: Front Immunol Date: 2018-10-05 Impact factor: 7.561
Authors: Tiira Johansson; Dawit A Yohannes; Satu Koskela; Jukka Partanen; Päivi Saavalainen Journal: Front Immunol Date: 2021-02-25 Impact factor: 7.561
Authors: Jun Zou; Piyanuch Kongtim; Betül Oran; Vasilis Kosmoliaptsis; Yudith Carmazzi; Junsheng Ma; Liang Li; Gabriela Rondon; Samer Srour; Hannah C Copley; David Partlow; Stefan O Ciurea; Uri Greenbaum; Qing Ma; Elizabeth J Shpall; Richard E Champlin; Kai Cao Journal: Haematologica Date: 2022-04-01 Impact factor: 9.941